Identifying biomarkers for a new ovarian cancer therapy
Developing biomarkers of response for a new therapy in ovarian cancer
['FUNDING_R01'] · UNIVERSITY OF PENNSYLVANIA · NIH-11036275
This study is looking at clear cell ovarian cancer and aims to find ways to predict which patients will respond best to a new treatment that targets specific genetic changes, so that doctors can personalize care and improve outcomes for those affected.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11036275 on ClinicalTrials.gov |
What this research studies
This research focuses on clear cell ovarian cancer (CCOC), a subtype that is difficult to treat due to its resistance to standard chemotherapy. The study aims to develop biomarkers that can predict how well patients will respond to a new combination therapy targeting specific genetic mutations. By analyzing human samples and using patient-derived tumor models, the researchers will identify which patients are most likely to benefit from this innovative treatment approach. The ultimate goal is to improve patient outcomes by personalizing therapy based on these biomarkers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with clear cell ovarian cancer, particularly those with ARID1A mutations.
Not a fit: Patients with other subtypes of ovarian cancer or those without ARID1A mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with clear cell ovarian cancer.
How similar studies have performed: Previous research has shown promise in using biomarkers to tailor cancer therapies, indicating that this approach could be effective.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SIMPKINS, FIONA — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: SIMPKINS, FIONA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.